Otonomy (NASDAQ:OTIC) Stock Passes Below 200-Day Moving Average of $0.32
Otonomy (NASDAQ:OTIC) Stock Passes Below 200-Day Moving Average of $0.32
Otonomy, Inc. (NASDAQ:OTIC – Get Rating)'s share price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.32 and traded as low as $0.11. Otonomy shares last traded at $0.11, with a volume of 1,426,584 shares.
Otonomy, Inc.(纳斯达克股票代码:OTIC — 获取评级)的股价在周三的交易中跌破了其200天移动平均线。该股的200天移动平均线为0.32美元,交易价格低至0.11美元。Otonomy股票最后一次交易价格为0.11美元,成交量为1,426,584股。
Analyst Upgrades and Downgrades
分析师升级和降级
OTIC has been the topic of a number of research reports. Piper Sandler cut Otonomy from an "overweight" rating to a "neutral" rating and lowered their price objective for the company from $3.00 to $0.50 in a research report on Thursday, October 13th. StockNews.com started coverage on Otonomy in a research report on Thursday. They issued a "hold" rating for the company.
OTIC 一直是许多研究报告的主题。派珀·桑德勒在10月13日星期四的一份研究报告中将Otonomy的评级从 “增持” 下调至 “中性”,并将公司的目标价格从3.00美元下调至0.50美元。StockNews.com在周四的一份研究报告中开始报道Otonomy。他们为该公司发布了 “持有” 评级。
Otonomy Price Performance
Otonomy 价格表现
The company's 50-day moving average is $0.11 and its two-hundred day moving average is $0.32. The company has a market cap of $7.10 million, a P/E ratio of -0.14 and a beta of 1.55.
该公司的50天移动平均线为0.11美元,其200天移动平均线为0.32美元。该公司的市值为710万美元,市盈率为-0.14,beta为1.55。
Hedge Funds Weigh In On Otonomy
对冲基金权衡自主权
A number of hedge funds have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. bought a new position in Otonomy in the third quarter valued at approximately $1,621,000. Lynx1 Capital Management LP boosted its holdings in Otonomy by 7,609.6% in the third quarter. Lynx1 Capital Management LP now owns 2,312,880 shares of the biopharmaceutical company's stock worth $682,000 after acquiring an additional 2,282,880 shares in the last quarter. Requisite Capital Management LLC purchased a new stake in shares of Otonomy during the third quarter valued at approximately $44,000. Dimensional Fund Advisors LP boosted its holdings in shares of Otonomy by 17.7% in the first quarter. Dimensional Fund Advisors LP now owns 841,694 shares of the biopharmaceutical company's stock worth $2,020,000 after acquiring an additional 126,747 shares during the period. Finally, Two Sigma Investments LP lifted its stake in Otonomy by 129.2% during the third quarter. Two Sigma Investments LP now owns 142,183 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 80,153 shares during the last quarter. Institutional investors and hedge funds own 41.23% of the company's stock.
一些对冲基金最近增加了或减少了在该业务中的股份。Point72 Asset Management L.P. 在第三季度购买了Otonomy的新头寸,价值约为16.1万美元。Lynx1 Capital Management LP在第三季度将其在Otonomy的持股量增加了7,609.6%。Lynx1 Capital Management LP在上个季度又收购了2,282,880股股票后,现在拥有这家生物制药公司的2312,880股股票,价值68.2万美元。Requiend Capital Management LLC在第三季度购买了Otonomy的新股份,价值约为44,000美元。Dimension Fund Advisors LP在第一季度将其持有的Otonomy股票增加了17.7%。在此期间又收购了126,747股股票后,Dimension Fund Advisors LP现在拥有这家生物制药公司的841,694股股票,价值202万美元。最后,Two Sigma Investments LP在第三季度将其在Otonomy的股份提高了129.2%。Two Sigma Investments LP在上个季度又购买了80,153股股票后,现在拥有这家生物制药公司142,183股股票,价值42,000美元。机构投资者和对冲基金拥有该公司41.23%的股票。
Otonomy Company Profile
Otonomy 公司简介
(Get Rating)
(获取评分)
Otonomy, Inc operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss.
Otonomy, Inc是一家生物制药公司。从事神经病学疗法的开发。该公司的产品线包括OTIVIDEX(地塞米松)梅尼尔病、OTIPRIO(环丙沙星视力悬浮液)急性带管中耳炎(AOMT)、OTO-313(加环素)耳鸣、OTO-413(BDNF)隐性听力损失、OTO-510(耳保护剂)预防CIHL、OTO-6XX(毛细胞再生)严重听力损失。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Otonomy (OTIC)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
- 免费获取 StockNews.com 关于自主学的研究报告(OTIC)的副本
- 细价股值得吗?你应该投资细价股吗?
- Zimmer Biomet的收益超过预期,增长可能会被定价
- 人工智能软件制造商 EPAM 拥有最大的科技板块涨势
- 在收益大幅下滑之后,福特股票将向前发展
- 内部人士和机构在全球范围内收购金刚狼
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Otonomy Daily 的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Otonomy及相关公司的最新新闻和分析师评级的简明每日摘要。